• A new investor, Redmile Group, enters the capital of Sensorion – existing investors, Invus and Sofinnova Partners, reinvest significantly.
• This new financing will allow the Company to extend its cash horizon until the end of September 2024.
• As part of the Private Placement, entry of Redmile Group to the Board of Directors, replacing Bpifrance Investissement, whose permanent representative was Mr. Jean-François Morin.
Montpellier, August 3, 2023, 7:00 p.m. CET – Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company dedicated to the development of innovative therapies to restore, treat and prevent hearing loss, today announces the completion a €35 million private placement financing reserved for qualified investors (the “Private Placement”) pursuant to the terms of definitive agreements signed by the Company with Redmile Group, a US-based healthcare investor Unis, and the existing shareholders of Sensorion, Invus and Sofinnova Partners, providing for (i) the subscription by these investors of 107,142,856 ordinary shares newly issued by the Company (the “New Shares”) at a price per New Share of 0, €28 (the “Subscription Price”) and (ii) the subscription by Redmile Group of 17,857,143 pre-funded stock warrants (the “BSAs”))